Standout Papers
- Updated efficacy and safety data from IMbrave150: Atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma (2021)
- Predictive and Prognostic Impact of Epidermal Growth Factor Receptor Mutation in Non–Small-Cell Lung Cancer Patients Treated With Gefitinib (2005)
- IMbrave150: Updated overall survival (OS) data from a global, randomized, open-label phase III study of atezolizumab (atezo) + bevacizumab (bev) versus sorafenib (sor) in patients (pts) with unresectable hepatocellular carcinoma (HCC). (2021)
Immediate Impact
5 by Nobel laureates 13 from Science/Nature 109 standout
Citing Papers
The anti-PD-L1/CTLA-4 bispecific antibody KN046 plus lenvatinib in advanced unresectable or metastatic hepatocellular carcinoma: a phase II trial
2025 Standout
Targeting the tumour vasculature: from vessel destruction to promotion
2024 Standout
Works of Tae‐You Kim being referenced
Updated efficacy and safety data from IMbrave150: Atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma
2021 Standout
Nivolumab (NIVO) + ipilimumab (IPI) combination therapy in patients (pts) with advanced hepatocellular carcinoma (aHCC): Subgroup analyses from CheckMate 040.
2020
Author Peers
| Author | Last Decade | Papers | Cites | |||
|---|---|---|---|---|---|---|
| Tae‐You Kim | 4224 | 2480 | 1973 | 183 | 7.4k | |
| Mario Scartozzi | 3645 | 2017 | 1628 | 335 | 6.2k | |
| Allen Lee Cohn | 4629 | 2314 | 1500 | 158 | 6.7k | |
| David Khayat | 5160 | 2557 | 2334 | 103 | 8.2k | |
| Alain Hendlisz | 5080 | 1959 | 1055 | 204 | 6.9k | |
| Jianming Xu | 3681 | 2861 | 1093 | 210 | 6.3k | |
| J. Randolph Hecht | 6948 | 2627 | 2412 | 115 | 9.0k | |
| Edwin P. Hui | 3857 | 1714 | 2136 | 170 | 8.7k | |
| Robert R. McWilliams | 5770 | 1859 | 2351 | 204 | 8.1k | |
| Enrico Cortesi | 4581 | 2398 | 1158 | 261 | 6.9k | |
| Chiun Hsu | 3125 | 1384 | 1881 | 222 | 7.2k |
All Works
Loading papers...